Atavistik, a computational biology platform company, and Lux Capital/Column Group investment, is focused on developing transformative small molecule therapeutics by revolutionizing the discovery and interrogation of new allosteric protein-metabolite interactions.
Bryan Stuart joins a formidable constellation of investors and operators, including Chairman John Josey, former CEO of Peloton Therapeutics which sold to Merck for over $1B, and Marion Dorsch, R&D heavyweight and former scientific leader at Blueprint and Agios.
Stuart was most recently CEO of Fulcrum, where he initially served as Chief Operating Officer. Prior to Fulcrum, he served as President and CEO of Yarra Therapeutics (a subsidiary of Array BioPharma) and CEO of Kastle Therapeutics. Previously, Stuart served as Chief Business Officer of Civitas Therapeutics (acquired by Acorda Therapeutics) and also led business development, corporate development, and strategy at both EKR Therapeutics (acquired by Chiesi Farmaceutici) and Ovation Pharmaceuticals (acquired by Lundbeck A/S).
Stuart earned his MBA from the Kellogg School at Northwestern University and his bachelor’s degree from the University of Illinois.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.